Figure 2.

Antibody responses based on homologous versus heterologous use of mRNA vaccines

Antibody responses to the receptor-binding domain (RBD) of the spike protein, the spike protein, and the nucleocapsid protein, based on homologous versus heterologous use of mRNA vaccines. Homologous vaccination consisted of both doses being either mRNA-1273 or BNT162b2, whereas heterologous vaccination consisted of mRNA-1273 followed by BNT162b2. Medians are indicated by diamonds, the IQR values are indicated by horizontal segments, and saturation thresholds are indicated by dashed lines. t1=before first dose. t2=approximately 4 weeks after first dose. t3=6–10 weeks after first dose. t4=up to 2 days before administration of second dose (16 weeks after prime dose). t5=4 weeks after second dose.